CREBBP and posterior cortical atrophy: Building on this finding, we evaluated various chemical inhibitors targeting the EP300/CREBBP HAT domain (A485, C646) and the BRD (CCS1477, I-CBP112, SGC-CBP30) (Fig. 1a) to assess their impact on PCa cell proliferation.